Session 37
Tumor – Gliome 4

Programm

• 09:30 – 09:40 7 Min. 3 Min.

  • Abstractvortrag | Abstract talk
  • V225

  Tumor-associated microglia/macrophages modulate progression of malignant glomas via xCT and angiogenic gene expression

  • Eduard Yakubov (Nuremberg)
  • Daishi Chen (Shenzhen / CN)
  • Nicolai Savaskan (Erlangen)
  • Karl-Michael Schebesch (Nuremberg)

   Tumor
• 09:40 – 09:50 7 Min. 3 Min.

  • Abstractvortrag | Abstract talk
  • V226

  CMV infection in glioblastoma – Oncomodulation through changes to the glioma immune landscape

  • Harald Krenzlin (Mainz)
  • Felix Corr (Mainz)
  • Philipp Einhäuser (Mainz)
  • Niels Lemmermann (Mainz)
  • Florian Ringel (Mainz)
  • Sean Lawler (Providence, RI / US)
  • Naureen Keric (Mainz)

   Tumor
• 09:50 – 10:00 7 Min. 3 Min.

  • Abstractvortrag | Abstract talk
  • V227

  EVA, a novel therapeutic targeting rationale for the treatment of glioblastoma

  • Tillmann Rusch (Baldingerstrasse)
  • Kai Zhao (Marburg)
  • Andreas Neubauer (Baldingerstrasse)
  • Christopher Nimsky (Marburg)
  • Jörg-Walter Bartsch (Marburg)

   Tumor
• 10:00 – 10:10 7 Min. 3 Min.

  • Abstractvortrag | Abstract talk
  • V228

  Dexamethasone presents an epigenetic effect on DNA methylation in glioblastoma

  • Anna-Maria Barciszewska (Posen / PL)
  • Agnieszka Belter (Posen / PL)
  • Małgorzata Giel-Pietraszuk (Posen / PL)
  • Iwona Gawronska (Posen / PL)
  • Mirosława Naskręt-Barciszewska (Posen / PL)

   Tumor
• 10:10 – 10:20 7 Min. 3 Min.

  • Abstractvortrag | Abstract talk
  • V106

  Evolution of neurosurgical results and survival of patients with newly diagnosed glioblastoma in two decades: Comparison of the results of two prospective, controlled trials on the resection of glioblastoma with comparable inclusion criteria: The 5-ALA and the iMRI vs. 5-ALA trials

  • Constantin Roder (Tübingen)
  • - iMRI/ALA study group (Germany)
  • - ALA-glioma study group (Germany)
  • Patrick Haas (Tübingen)
  • Marcos Tatagiba (Tübingen)
  • Peter Martus (Tübingen)
  • Walter Stummer (Münster)

   Tumor
• 10:20 – 10:30 7 Min. 3 Min.

  • Abstractvortrag | Abstract talk
  • V230

  Individualized multimodal immunotherapy added to standard care of glioblastoma multiforme improves the overall survival

  • Petra Zilliken (Köln)

   Tumor